Trillium Therapeutics Inc.
(Toronto Stock Exchange : TRIL)

( )
TRIL After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
TSROTESARO, Inc.
-1.07%73.6914.4%$580.10m
AMGNAmgen Inc.
-2.76%192.071.2%$565.07m
GILDGilead Sciences, Inc.
-2.64%65.570.9%$530.36m
CELGCelgene Corporation
-2.21%68.201.2%$520.26m
BIIBBiogen Inc.
-1.75%314.551.3%$359.40m
ILMNIllumina, Inc.
-2.44%326.463.5%$350.15m
REGNRegeneron Pharmaceuticals, Inc.
0.70%381.172.6%$273.12m
VRTXVertex Pharmaceuticals Incorporated
-1.94%170.061.9%$226.47m
AAgilent Technologies, Inc.
-2.49%69.371.5%$225.54m
ALXNAlexion Pharmaceuticals, Inc.
-2.67%109.432.0%$146.61m
INCYIncyte Corporation
-1.55%66.252.5%$97.76m
EXASExact Sciences Corporation
0.68%68.3125.3%$93.39m
SRPTSarepta Therapeutics, Inc.
-2.05%119.5215.4%$90.77m
NKTRNektar Therapeutics
-3.92%36.515.5%$84.08m
SGENSeattle Genetics, Inc.
-0.85%60.486.6%$81.91m

Company Profile

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company, which engages in the development of innovative therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-2341(EGFR Inhibitor). The company was founded on March 31, 2004 and is headquartered in Toronto, Canada.